This episode discusses two MMWR reports. The first highlights ACIP's interim recommendation for the use of the Pfizer-BioNTech COVID-19 Vaccine in children ages 5-11 years. And the second looks at the effectiveness of mRNA vaccination among immunocompromised and immunocompetent adults.
This episode discusses two MMWR reports. The first highlights ACIP's interim recommendation for the use of the Pfizer-BioNTech COVID-19 Vaccine in children ages 5-11 years. And the second looks at the effectiveness of mRNA vaccination among immunocompromised and immunocompetent adults.